- Combination therapy of nimacimab (SKYE, Financial) with tirzepatide led to over 30% weight loss in preclinical trials.
- Nimacimab alone showed a 23.5% weight loss, comparable to existing treatments.
- Nimacimab's unique binding mechanism may offer better safety and efficacy.
Skye Bioscience (SKYE), a clinical-stage biotechnology company, has announced promising preclinical results for its CB1 antibody, nimacimab, in treating obesity. In a diet-induced obesity model, the combination of nimacimab with tirzepatide led to over 30% weight loss after just 25 days of treatment. As a monotherapy, nimacimab demonstrated a 23.5% weight loss, performing on par with the standard treatments monlunabant and tirzepatide.
New in vitro data highlighted nimacimab's superior potency, attributed to its non-competitive allosteric binding to the CB1 receptor. Unlike monlunabant, nimacimab maintains stable effectiveness even under high agonist concentrations, suggesting potential advantages in treating obesity without the neuropsychiatric side effects associated with traditional CB1 inhibitors.
The company anticipates releasing top-line randomized data from the Phase 2a CBeyondâ„¢ study in late Q3/early Q4 2025. This advancement positions nimacimab as a potential standalone or combination therapy with GLP-1 targeted drugs, addressing the unmet needs in obesity treatment with a promising safety profile.
